<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00143793</url>
  </required_header>
  <id_info>
    <org_study_id>80/05</org_study_id>
    <nct_id>NCT00143793</nct_id>
  </id_info>
  <brief_title>NT-proBNP and New Biomarkers in Patients With Dyspnea and/or Peripheral Edema</brief_title>
  <acronym>MANPRO</acronym>
  <official_title>Mannheim NT-proBNP Study (MANPRO) Evaluating NT-proBNP and New Biomarkers in Patients Suffering From Dyspnea and/or Peripheral Edema for the Differential Diagnosis of Congestive Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universit채tsmedizin Mannheim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universit채tsmedizin Mannheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to:&#xD;
&#xD;
        -  Evaluate the sensitivity and specificity of NT-proBNP (N-terminal prohormone brain&#xD;
           natriuretic peptide) and new biomarker measurements for the diagnosis of heart failure&#xD;
           in patients with acute dyspnea and/or edema.&#xD;
&#xD;
        -  Determine the exact biomarker cut-off point(s) for the differentiation of healthy&#xD;
           persons, patients with heart failure and patients with dyspnea of other origin.&#xD;
&#xD;
        -  Evaluate treatment costs in patients with dyspnea under special consideration of&#xD;
           NT-proBNP measurement.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary endpoint:&#xD;
&#xD;
        -  Sensitivity and specificity of biomarker measurements for discrimination of heart&#xD;
           failure from dyspnea of other origin.&#xD;
&#xD;
      Secondary endpoints:&#xD;
&#xD;
        -  Determination of Cut-off(s)&#xD;
&#xD;
        -  Discrimination of cardiac and non-cardiac diseases causing to dyspnea or peripheral&#xD;
           edema&#xD;
&#xD;
        -  Determination of treatment costs of the initial hospital stay&#xD;
&#xD;
        -  Evaluation of resource savings when implementing NT-proBNP for determination of&#xD;
           diagnosis.&#xD;
&#xD;
        -  Time to diagnosis.&#xD;
&#xD;
        -  Hospitalization rate /Intensive care treatment rate between day 1 and 28&#xD;
&#xD;
        -  Duration of initial hospital stay&#xD;
&#xD;
        -  30-day re-hospitalization rate&#xD;
&#xD;
        -  30 day mortality rate and adverse event rate&#xD;
&#xD;
        -  1 and 5 year mortality rates&#xD;
&#xD;
        -  1 and 5 year rehospitalization rates&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2005</start_date>
  <completion_date type="Actual">December 2019</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Dyspnea</condition>
  <condition>Peripheral Edema</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients suffering from dyspnea and peripheral edema&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-90 years&#xD;
&#xD;
          -  Dyspnea or/and peripheral edema&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Renal insufficiency with creatinine &gt; 2.8mg/dl&#xD;
&#xD;
          -  Anemia (hemoglobin &lt; 8.0mg/dl)&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martina Brueckmann, MD</last_name>
    <role>Study Chair</role>
    <affiliation>First Department of Medicine, University Medical Centre Mannheim</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Borggrefe, MD</last_name>
    <role>Study Chair</role>
    <affiliation>First Department of Medicine, University Medical Centre Mannheim</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Neumaier, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Clinical Chemistry, University Medical Centre Mannheim</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Parviz Ahmad-Nejad, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institute of Clinical Chemistry, University Medical Centre Mannheim</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Behnes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Department of Medicine, University Medical Centre Mannheim</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ursula Hoffmann, MD</last_name>
    <role>Study Chair</role>
    <affiliation>First Department of Medicine, University Medical Centre Mannheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Faculty Mannheim, University of Heidelberg</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-W체rttemberg</state>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 31, 2005</study_first_submitted>
  <study_first_submitted_qc>August 31, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2005</study_first_posted>
  <last_update_submitted>August 26, 2020</last_update_submitted>
  <last_update_submitted_qc>August 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universit채tsmedizin Mannheim</investigator_affiliation>
    <investigator_full_name>Michael Behnes</investigator_full_name>
    <investigator_title>Dr. med.</investigator_title>
  </responsible_party>
  <keyword>natruretic peptides</keyword>
  <keyword>NT-proBNP</keyword>
  <keyword>new biomarkers</keyword>
  <keyword>congestive heart failure</keyword>
  <keyword>atrial fibrillation</keyword>
  <keyword>acute myocardial infarction</keyword>
  <keyword>lung embolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspnea</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

